We are super excited to announce that DeepPath receives CE marking for DeepPath- LYDIA. The system got regulatory clearance as decision support as per IVDD for helping histopathologists detect metastases on Hematoxylin & Eosin stained lymph nodes from patients with breast cancer, colon cancer, lung cancer, and melanoma.
We must note that to the best of our knowledge, DeepPath – LYDIA is the only CE-marked AI-powered metastasis detection system that concurrently detects tumor lesions from four different types, thus covering ~43% of total cancer cases.
The system analyses digitised microscope slides and presents the detected tumor regions to the histopathologists for inspection, which has been shown to accelerate the diagnostic process by up to 5 times, while at the same time increasing accuracy!
Our next goal is to deploy the system in hospitals across #europe and the menaregion!
